Right now, that's none other than Eli Lilly (NYSE: LLY). However, others are looking to challenge its dominance. Recent comments from Pfizer 's (NYSE: PFE) CEO, Albert Bourla, suggest it could become ...

Tuesday, November 18, 2025 The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Microsoft ...

South Korean clinical-stage biotech ABL Bio has entered license, research and collaboration agreement with US pharma major Eli Lilly for the development of therapeutics by utilizing ABL Bio’s Grabody ...

Novo Nordisk, the Danish pharmaceutical company that has long dominated the obesity treatment market, significantly lowered ...

Novo Nordisk A/S (NYSE:NVO) is one of the stocks Jim Cramer expressed his thoughts on. A caller asked, as a long-time holder ...

American Express is an advertising partner of Motley Fool Money. The Motley Fool has positions in and recommends Amazon, Peloton Interactive, and Pfizer. The Motley Fool recommends Coinbase Global and ...

Celebrity endorsements by Elon Musk and Serena Williams have pushed weight loss medication into the mainstream. Demand is so ...

Winrevair, which Merck has identified as a “growth driver,” significantly improved blood flow through the lungs to the heart in a study of adults with a common form of heart failure.

Founded in 2016 at the dawn of distributed computing for scientific breakthroughs, GNUS.ai drew inspiration from initiatives like Folding@home, which pioneered GPU crowdsourcing to combat diseases ...

Major stock indexes ended sharply lower to begin the week, which will see AI darling Nvidia and retail giants report ...

A new word is making the rounds in the business press: "anti-involution." In recent years, Chinese companies have built ...

Eli Lilly shares have room to keep going as GLP-1 drugs spread their reach.